Bharat Biotech Introduces India's First Integrated Cell & Gene Therapy

Bharat Biotech International Limited (BBIL) has expanded its expertise from vaccine innovation to cutting-edge regenerative and personalized therapies that offer hope to millions of people by establishing India's only vertically integrated...

India's specialty chemicals recover as pharma exports continue strong growth

India's specialty chemicals industry is bouncing back in Q4 FY25, while pharma exports continue to grow at 8-9% backed by sustained demand for...

CAR-T therapy to transform cancer treatment in India

As society grows in knowledge and confidence regarding an available policy, training, and infrastructure, CAR-T cell therapy will shake up...

Eli Lilly launches Mounjaro in India for obesity & diabetes management

Eli Lilly and Company has launched Mounjaro in a single-dose vial, which has been authorized to be marketed by the Central Drugs Standard Control Organization (CDSCO). This first-ever treatment drug...

AIMED Calls for Reassessment of Medical Device Import Duties

The central government has been urged to reconsider discussions about reducing import taxes on medical devices from the United States by the Association of Indian Medical Device Industry (AIMED). According to the industry organization, these changes

Tech Mahindra, NVIDIA Partner for AI-Powered Drug Safety Innovation

In a tactical initiative to improve drug safety oversight, Tech Mahindra, a worldwide frontrunner in technology consulting and digital services, has revealed an AI-based pharmacovigilance (PV) solution utilizing NVIDIA AI software. The solution seeks

Zydus Lifesciences Secures USFDA Approval for Generic Prostate Cancer Drug

Zydus Lifesciences Limited has established itself as a strong player in the world oncology market with its recent FDA approval to manufacture and sell a generic version of Apalutamide 60 mg tablets for the treatment of prostate cancer. The drug will

Cellogen Therapeutics secures patent for world's first bi-specific CAR T

A major achievement for India's biotech industry and cancer treatment has occurred as the Delhi-based startup Cellogen Therapeutics has received...

USV unveils empagliflozin and combinations for diabetes care in India

The main SGLT2 inhibitor Xenia (empagliflozin and its combos) was introduced by USV, an Indian global healthcare business, to treat type 2 diabetes patients' heart failure, chronic renal disease, and glycaemic management.

London Biotechnology Show Elevates the Biotech Landscape with a Stellar Exhibitor Lineup, Hosted Buyer Programme

LONDON, UK - March 19: The much-anticipated second annual edition of the Biotechnology Show continues to attract industry giants, creating a powerful platform for innovation, collaboration, and deal-making.

© 2025 India Pharma Outlook. All Rights Reserved.